|
Quotes & Info
|
| IVC > SEC Filings for IVC > Form 8-K on 21-Dec-2012 | All Recent SEC Filings |
21-Dec-2012
Entry into a Material Definitive Agreement, Costs Associated with Exit or Disposal
On December 21, 2012, Invacare Corporation, an Ohio corporation (the "Company"),
and its wholly-owned subsidiary, Invacare Supply Group, Inc. ("ISG"), entered
into a Share Purchase Agreement (the "Purchase Agreement") with AssuraMed, Inc.
(the "Purchaser"). Pursuant to the Purchase Agreement, the Purchaser will
acquire all of the issued and outstanding capital stock of ISG from the Company
for $150 million in cash (the "Transaction"), the terms of which are described
below. The purchase price also will be subject to certain closing adjustments as
described further in the Purchase Agreement. Subject to certain closing
adjustments and any restructuring charges, the Company preliminarily estimates
that it will realize net proceeds from the Transaction of approximately $140
million, net of tax and expenses. The Transaction is expected to close in early
2013.
Consummation of the Transaction is subject to certain customary closing
conditions, including, among others, the expiration of the Hart-Scott-Rodino Act
waiting period. The obligations of the parties to close the Transaction also are
subject to the accuracy of representations and warranties of, and compliance
with covenants by, the other party as set forth in the Purchase Agreement (in
each case subject to materiality) and, in the case of the Purchaser's
obligations, the absence of any material adverse change affecting ISG.
The Purchase Agreement contains customary indemnification obligations of each
party with respect to breaches of their respective representations, warranties
and covenants, and certain other specified matters, which are subject to certain
exceptions, terms and limitations described further in the Purchase Agreement.
The parties to the Transaction have made customary representations and
warranties, and covenants, including with respect to the conduct of the business
of ISG during the interim period between the execution of the Purchase Agreement
and the closing of the Transaction.
The representations, warranties and covenants set forth in the Purchase
Agreement have been made only for the purposes of such agreement and were solely
for the benefit of the parties to the Purchase Agreement, may be subject to
limitations agreed upon by the contracting parties, including being qualified by
confidential disclosures, may have been made for the purposes of allocating
contractual risk between the parties to the Purchase Agreement instead of
establishing these matters as facts, and may be subject to standards of
materiality applicable to the contracting parties that differ from those
applicable to investors. Accordingly, the Purchase Agreement is included with
this filing only to provide investors with information regarding the terms of
the Purchase Agreement, and not to provide investors with any other factual
information regarding the parties or their respective businesses, and should be
read in conjunction with the disclosures in the Company's periodic reports and
other filings with the Securities and Exchange Commission.
The Purchase Agreement contains a "no-shop" provision pursuant to which the
Company covenants not to negotiate, undertake or enter into any alternative
transaction involving the sale of ISG, solicit any such alternative transaction,
furnish information to any person in connection with any such alternative
transaction, or otherwise cooperate or assist with any attempt by any person to
seek such an alternative transaction.
At the closing of the Transaction, the parties will enter into a supply
agreement and a transition services agreement to provide certain transitional
services with respect to the ISG business following the Transaction. At closing,
the parties also will enter into an agreement containing certain non-competition
and
non-solicitation covenants of the Company with respect to the ISG business and
its employees after the closing.
The Purchase Agreement may be terminated by either the Company or the Purchaser
if the closing has not occurred by March 1, 2013 (subject to extension if
certain regulatory approvals have not been obtained by that date) or upon the
occurrence of certain customary events as set forth in the Purchase Agreement.
Neither the Company nor any of its affiliates have had a material relationship
with the Purchaser, other than in respect of the Purchase Agreement.
A copy of the Purchase Agreement is attached as Exhibit 2.1 to this Current
Report on Form 8-K and is incorporated in this Item 1.01 by reference. The
foregoing description of the Purchase Agreement is a summary, does not purport
to be complete and is qualified in its entirety by reference to the Purchase
Agreement.
In connection with the Transaction, the Company may incur material charges for exit and disposal activities under GAAP; however, at this time, the Company is unable, in good faith, to make a determination of an estimate of the total amount or range of amounts for each major type of cost expected to be incurred in connection with the Transaction, an estimate of the total amount or range of amounts expected to be incurred in connection with the divestiture, or an estimate of the amount or range of amounts of the charges that will result in future cash expenditures. If the Company makes a determination of any such estimates or ranges of estimates, and such amounts are material, the Company expects to file an amended Current Report on Form 8-K under this Item 2.05 within four business days after any such determination is made.
A press release announcing the Transaction was issued by the Company on December 21, 2012, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 8.01 by reference.
2.1 Share Purchase Agreement among AssuraMed, Inc. and Invacare
Corporation and Invacare Supply Group, Inc., dated December 21,
2012. (Pursuant to Item 601(b)(2) of Regulation S-K, the
registrant hereby agrees to supplementally furnish to the
Securities and Exchange Commission upon request any omitted
schedule or exhibit to the agreement.)
99.1 Press release, dated December 21, 2012
|
|
|